Calcium glucoheptonate

Identification

Name
Calcium glucoheptonate
Accession Number
DB00326
Description

Calcium supplements such as calcium gluceptate are taken by individuals who are unable to get enough calcium in their regular diet or who have a need for more calcium. They are used to prevent or treat several conditions that may cause hypocalcemia (not enough calcium in the blood). The body needs calcium to make strong bones. Calcium is also needed for the heart, muscles, and nervous system to work properly.

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 490.425
Monoisotopic: 490.084675939
Chemical Formula
C14H26CaO16
Synonyms
  • Calcii glucoheptonas
  • calcium (2ξ)-D-gluco-heptonate
  • calcium bis[(2ξ)-D-glycero-D-gulo-heptonate]
  • calcium bis[(2ξ)-D-glycero-D-ido-heptonate]
  • calcium bis[(3R,4S,5R,6R)-2,3,4,5,6,7-hexahydroxyheptanoate]
  • Calcium gluceptate
  • Calcium glucoheptonat
  • Calcium glucoheptonate
  • Calcium glucoheptonate (1:2)
  • Glucoheptonate de calcium
  • Glucoheptonato calcico

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication

For treatment of mild hypocalcemia due to neonatal tetany, tetany due to parathyroid deficiency or vitamin D deficiency, and alkalosis, as prophylaxis of hypocalcemia during exchange transfusions, in the treatment of intestinal malabsorption, and to replenish electrolytes.

Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Calcium supplements such as calcium gluceptate are taken by individuals who are unable to get enough calcium in their regular diet or who have a need for more calcium. They are used to prevent or treat several conditions that may cause hypocalcemia (not enough calcium in the blood). The body needs calcium to make strong bones. Calcium is also needed for the heart, muscles, and nervous system to work properly. The bones serve as a storage site for the body's calcium. They are continuously giving up calcium to the bloodstream and then replacing it as the body's need for calcium changes from day to day. When there is not enough calcium in the blood to be used by the heart and other organs, your body will take the needed calcium from the bones. When you eat foods rich in calcium, the calcium will be restored to the bones and the balance between your blood and bones will be maintained.

Mechanism of action

Calcium gluceptate replenishes the deminished levels of calcium in the body, returning them to normal levels.

Absorption

Rapidly absorbed following oral administration.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Symptoms of overdose include confusion, drowsiness (severe), high blood pressure, increased sensitivity of eyes or skin to light, irregular, fast, or slow heartbeat, and unusually large amount of urine or increased frequency of urination.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcebutololThe therapeutic efficacy of Acebutolol can be decreased when used in combination with Calcium glucoheptonate.
AcetyldigitoxinCalcium glucoheptonate may increase the arrhythmogenic and cardiotoxic activities of Acetyldigitoxin.
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Calcium glucoheptonate.
AlfacalcidolThe risk or severity of adverse effects can be increased when Calcium glucoheptonate is combined with Alfacalcidol.
AmiodaroneThe therapeutic efficacy of Amiodarone can be decreased when used in combination with Calcium glucoheptonate.
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium glucoheptonate.
AtenololThe therapeutic efficacy of Atenolol can be decreased when used in combination with Calcium glucoheptonate.
BendroflumethiazideBendroflumethiazide may decrease the excretion rate of Calcium glucoheptonate which could result in a higher serum level.
BenzthiazideBenzthiazide may decrease the excretion rate of Calcium glucoheptonate which could result in a higher serum level.
BepridilThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium glucoheptonate.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
No interactions found.

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
GlucoheptonateInjection, powder, lyophilized, for solution50 mg/1IntravenousAnazao Health Corporation2012-05-23Not applicableUS flag
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Calcium Liq AlsiLiquidOralAlsi Cie Ltee1980-12-312003-05-21Canada flag
Sirop De Calcium 625mg/5mlSyrupOralTherapex Division De E Z Em Canada Inc1980-12-311997-07-22Canada flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Calcium LiquidCalcium glucoheptonate (132 mg) + Calcium gluconate (112 mg)LiquidOralVita Health Products Inc1980-12-312002-07-31Canada flag
Calcium LiquidCalcium glucoheptonate (132 mg) + Calcium gluconate (112 mg)LiquidOralKsl Pharmaceuticals1994-12-311996-09-09Canada flag
Calcium LiquidCalcium glucoheptonate (132 mg) + Calcium gluconate (112 mg)LiquidOralShoppers Drug Mart Inc.1981-12-311997-08-15Canada flag
Liquid CalciumCalcium glucoheptonate (132 mg) + Calcium gluconate (112 mg)LiquidOralWampole Brands, A Division Of Pangeo Pharma (Canada) Inc.1998-08-122000-07-06Canada flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
GlucoheptonateCalcium glucoheptonate (50 mg/1)Injection, powder, lyophilized, for solutionIntravenousAnazao Health Corporation2012-05-23Not applicableUS flag

Categories

ATC Codes
A12AA10 — Calcium glucoheptonate
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as sugar acids and derivatives. These are compounds containing a saccharide unit which bears a carboxylic acid group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Sugar acids and derivatives
Alternative Parents
Heptoses / Medium-chain hydroxy acids and derivatives / Medium-chain fatty acids / Beta hydroxy acids and derivatives / Hydroxy fatty acids / Secondary alcohols / Carboxylic acid salts / Polyols / Organic calcium salts / Monocarboxylic acids and derivatives
show 6 more
Substituents
Alcohol / Aliphatic acyclic compound / Beta-hydroxy acid / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Carboxylic acid salt / Fatty acid / Fatty acyl / Heptose monosaccharide
show 15 more
Molecular Framework
Not Available
External Descriptors
calcium salt (CHEBI:3314)

Chemical Identifiers

UNII
L11651398J
CAS number
29039-00-7
InChI Key
FATUQANACHZLRT-KMRXSBRUSA-L
InChI
InChI=1S/2C7H14O8.Ca/c2*8-1-2(9)3(10)4(11)5(12)6(13)7(14)15;/h2*2-6,8-13H,1H2,(H,14,15);/q;;+2/p-2/t2*2-,3-,4+,5-,6?;/m11./s1
IUPAC Name
calcium bis((3R,4S,5R,6R)-2,3,4,5,6,7-hexahydroxyheptanoate)
SMILES
[Ca++].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O

References

General References
  1. Drop LJ, Cullen DJ: Comparative effects of calcium chloride and calcium gluceptate. Br J Anaesth. 1980 May;52(5):501-5. [PubMed:7387803]
Human Metabolome Database
HMDB0014471
KEGG Drug
D00934
PubChem Compound
62859
PubChem Substance
46507233
ChemSpider
56591
RxNav
47618
ChEBI
3314
ChEMBL
CHEMBL1237066
PharmGKB
PA164746233
Wikipedia
Calcium_glucoheptonate
MSDS
Download (68.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
  • Abbott laboratories pharmaceutical products div
  • Abraxis pharmaceutical products
  • Eli lilly and co
Packagers
  • Draxis Specialty Pharmaceuticals Inc.
  • Medi-Physics Inc.
  • Spectrum Pharmaceuticals
Dosage Forms
FormRouteStrength
LiquidOral
LiquidOral
Injection, powder, lyophilized, for solutionIntravenous50 mg/1
SyrupOral
Prices
Unit descriptionCostUnit
Calcium gluceptate powder12.69USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilitySolubleNot Available
Predicted Properties
PropertyValueSource
Water Solubility39.8 mg/mLALOGPS
logP-1.9ALOGPS
logP-4ChemAxon
logS-1.1ALOGPS
pKa (Strongest Acidic)3.38ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area161.51 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity55.07 m3·mol-1ChemAxon
Polarizability19.34 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption-0.9575
Blood Brain Barrier+0.5646
Caco-2 permeable-0.8513
P-glycoprotein substrateNon-substrate0.6616
P-glycoprotein inhibitor INon-inhibitor0.9743
P-glycoprotein inhibitor IINon-inhibitor0.9608
Renal organic cation transporterNon-inhibitor0.9445
CYP450 2C9 substrateNon-substrate0.8702
CYP450 2D6 substrateNon-substrate0.87
CYP450 3A4 substrateNon-substrate0.7334
CYP450 1A2 substrateNon-inhibitor0.8579
CYP450 2C9 inhibitorNon-inhibitor0.9163
CYP450 2D6 inhibitorNon-inhibitor0.9286
CYP450 2C19 inhibitorNon-inhibitor0.9106
CYP450 3A4 inhibitorNon-inhibitor0.9274
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9873
Ames testNon AMES toxic0.8429
CarcinogenicityNon-carcinogens0.838
BiodegradationReady biodegradable0.9895
Rat acute toxicity1.9804 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9838
hERG inhibition (predictor II)Non-inhibitor0.938
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on June 13, 2005 13:24 / Updated on March 04, 2021 11:10